Dogwood Therapeutics Halneuron® Phase 2b On Track; Antiviral Deal Up To $100M
Dogwood Therapeutics announced its Q2 2026 financial results, reporting a net loss of $11.5 million, significantly higher than the $3.8 million loss in Q2 2025, primarily due to a $9.2 million non-cash IPR&D impairment charge. Operationally, the company confirmed its Halneuron® Phase 2b trial is on track for top-line results in Fall 2026, with 217 patients enrolled, and commenced a long-term extension study. Additionally, SP16 received IND approval, and Dogwood secured a worldwide development and commercialization partnership for antiviral assets with a potential value of up to $100 million. The company also appointed Iain Dukes as Chair of its Scientific Advisory Board and has $9.6 million in cash, providing an operational runway through Q4 2026.
Key Highlights
- Halneuron® Phase 2b trial on track for top-line results in Fall 2026 with 217 patients enrolled.
- Commenced Phase 2b Long-Term Extension Study for Halneuron® to assess pain reduction over three months.
- SP16 granted IND approval from FDA; study to begin enrolling in H2 2026.
- Announced worldwide development and commercialization partnership for antiviral assets with potential value up to $100M.
- Appointed Iain Dukes, D.Phil., as Chair of Scientific Advisory Board.
- Reported Q2 2026 net loss of $11.5 million, compared to $3.8 million in Q2 2025.
- Recognized a non-cash IPR&D impairment charge of $9.2 million in Q2 2026.
- Cash on hand of $9.6 million provides operational runway through Q4 2026.
Price Impact
More from DWTX